IND versus BLA: what the CMC sections must show

IND and BLA filing ask different CMC questions, and treating them as one document at two sizes causes most delays. 21 CFR 312.23(a)(7) asks for enough information to assure "the proper identification, quality, purity, and strength" of the investigational product, scaled to the phase of study. 21 CFR 601.2 asks for a full description of manufacturing methods and data establishing stability through the dating period. The table sets the two side by side.

Two consequences follow. An IND can be filed with a process that will change; a BLA cannot. And the reviewer traces every clinical lot back through comparability to the licensed process, so lot genealogy must be recorded from the first GMP batch.

Pre-IND: the minimum CMC package

The minimum pre-IND CMC package is the data that lets the FDA conclude the Phase 1 material will not expose subjects to unreasonable risk, and nothing more; it is the first deliverable in IND and BLA filing. FDA's 1995 guidance on the content and format of INDs for Phase 1 studies remains the reference for scope. The package contains:

• Drug substance description: source, expression system and cell bank.
• Manufacturing flow diagram with scale, unit operations and raw materials.
• Test methods and preliminary acceptance criteria, emphasizing safety attributes: sterility, endotoxin, mycoplasma, adventitious agents, host cell DNA and protein.
• Viral clearance evaluation appropriate to the process and cell substrate (ICH Q5A).
• Stability data on the toxicology and clinical lots plus a protocol; drug product composition and container closure.

A pre-IND meeting is the point to confirm that toxicology and clinical material are comparable and the specification adequate. After submission, 21 CFR 312.40 imposes a 30-day wait before dosing; CMC deficiencies raised in that window are a common cause of clinical hold.

Phase-appropriate GMP through Phase 1–3

GMP expectations rise with each clinical phase, and the practical task between IND and BLA filing is to make each step of that rise deliberate rather than reactive. FDA's 2008 guidance on cGMP for Phase 1 investigational drugs exempts Phase 1 material from the full requirements of 21 CFR Part 211, while the statutory cGMP requirement under section 501(a)(2)(B) of the FD&C Act still applies. A phase-appropriate program moves through three states:

1. Phase 1: qualified methods, documented process, controlled raw materials, full batch records. Process changes are expected.
2. Phase 2: methods move toward validation, the specification tightens around clinical experience, and the process is locked for the end-of-Phase 2 meeting.
3. Phase 3: pivotal lots are made by the intended commercial process at the intended scale and site, or bridged to it under ICH Q5E. Methods are validated before PPQ.

The end-of-Phase 2 meeting is the place to agree the CMC plan for Phase 3: remaining process changes, how comparability will be shown, how many PPQ lots are planned and what stability will exist at submission.

BLA readiness: PPQ, stability data, comparability

A BLA is ready when three CMC packages close at the same time: process performance qualification, real-time stability, and the comparability chain linking clinical lots to the commercial process. Each has its own lead time, and the longest of the three sets the back end of the IND and BLA filing timeline.

PPQ. Under FDA's 2011 process validation guidance, Stage 2 PPQ demonstrates that the commercial process, at the commercial site and scale, reproducibly delivers product meeting its specification. The number of lots is justified, not fixed at three. The PPQ report is filed under 3.2.S.2.5 and must be complete at submission.

Stability. ICH Q5C requires real-time, real-condition data, because accelerated data cannot reliably predict protein degradation. The shelf life must be supported by lots representative of the commercial process, which usually means PPQ lots. Sponsors place PPQ lots on stability immediately and commit to update during review.

Comparability. Every process version used in pivotal studies must be bridged to the licensed process with analytical and, where needed, non-clinical or clinical data. The pre-BLA meeting should confirm the strategy before the dossier is written.

Pre-license inspection readiness

Inspection readiness is the last CMC gate in IND and BLA filing: the FDA may conduct a pre-license inspection of each manufacturing site named in the BLA, and the outcome is a condition of approval. The inspection verifies that the facility, equipment, process and quality system described in Module 3 exist as described and operate under cGMP. Readiness work falls into four areas:

• Dossier-to-floor consistency: batch records, SOPs and equipment lists match 3.2.S.2, including scale, column dimensions and in-process limits.
• Data integrity: raw data for PPQ, stability and release is retrievable, attributable and audit-trailed.
• Quality system evidence: deviations, CAPAs and change controls from the PPQ campaign closed with impact assessments.
• People: subject-matter experts briefed and a procedure for answering requests within the inspection day.

Where a CDMO is the site, the quality agreement should state who hosts, who answers, and how observations are shared. A site already approved by the FDA for another product carries lower, but not zero, inspection risk.

Timeline from IND to BLA

From IND submission to BLA action, a biologic program typically runs six to eight years, with CMC on the critical path for at least two of them. The table shows a representative IND and BLA filing sequence; durations are typical ranges, not requirements.

Two scheduling rules follow. PPQ must finish early enough for real-time stability on PPQ lots to be meaningful at submission, which pushes PPQ into the Phase 3 period. And only the site that made the PPQ lots can pass the pre-license inspection, so a late site change restarts the clock on IND and BLA filing readiness.

Where a CDMO's regulatory support fits

A CDMO's regulatory support for IND and BLA filing is concentrated in Module 3, the facility sections of the application and the inspection, while the sponsor retains the application and the strategy. The interface points are:

• Content authorship: 3.2.S.2 Manufacture, 3.2.S.4 validation reports, and the PPQ and viral clearance reports, in CTD-ready format.
• Review responses: information requests during review need batch data and method detail only the CDMO holds; turnaround commitments belong in the quality agreement.
• Multi-region alignment: a CDMO that has supplied content for both an FDA BLA and an EMA MAA can keep one core Module 3 with regional annexes.

When evaluating regulatory support for IND and BLA filing, ask which agencies have inspected the site and when, and which products the CDMO has carried through PPQ.